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Abstract
Background: Warfarin is commonly used as a secondary prevention of stroke in patients with atrial fibrillation (AF).
However, limitations have been observed even with the use of this medication. Recently, several newer direct oral
anticoagulants (DOACs) have been approved for use by the food and drug administrations. Unfortunately, these
newer drugs have seldom been compared directly with each other. Therefore, this study aimed to compare the
bleeding events associated with rivaroxaban and dabigatran in patients treated for non-valvular AF.
Methods: EMBASE, Medline (National Library of Medicine) and the Cochrane Central Registry of Controlled Trials
were searched for studies comparing rivaroxaban with dabigatran using the terms ‘rivaroxaban, dabigatran and
atrial fibrillation’. Primary endpoints were: any bleeding outcomes, intracranial bleeding and gastro-intestinal (GI)
bleeding. Secondary outcomes included stroke/systemic embolism (SE)/transient ischemic attack (TIA), venous
thromboembolism and mortality. Odds ratios (OR) with 95% confidence intervals (CIs) were calculated. The
pooled analyses were carried out with RevMan 5.3 software. All the authors had full access to the data and
approved the manuscript as written.
Results: A total number of 4895 patients were included. This analysis showed that rivaroxaban was not associated
with a significantly higher bleeding event when compared to dabigatran (OR: 1.28, 95% CI: 0.95–1.72; P = 0.11).
GI bleeding was similarly manifested between these two DOACs (OR: 0.98, 95% CI: 0.43–2.25; P = 0.97). Even if
intracranial bleeding was higher with the use of rivaroxaban, (OR: 2.18, 95% CI: 0.51–9.25; P = 0.29), the result was
not statistically significant. Moreover, stroke/SE/TIA and venous thromboembolism were also not significantly different
(OR: 0.81, 95% CI: 0.53–1.23; P = 0.32) and (OR: 2.06, 95% CI: 0.73–5.82; P = 0.17) respectively. However, even if mortality
favored dabigatran (OR: 1.42, 95% CI: 0.99–2.06; P = 0.06), this result only approached statistical significance.
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Conclusion: Head to head comparison showed that rivaroxaban was not associated with significantly higher bleeding
events compared to dabigatran. Intracranial bleeding, GI bleeding, stroke/SE/TIA, venous thromboembolism and
mortality were also not significantly different between these two DOACs. However, due to the limited number of
patients analyzed, and which were mainly obtained from observational studies, this hypothesis might only be
confirmed in future randomized trials. Furthermore, the CHADS2-VASC and HAS-BLED score which might play an
important role in predicting bleeding risks should also not be ignored.
Keywords: Atrial fibrillation, Rivaroxaban, Dabigatran, Bleeding events, Intracranial bleeding, Gastrointestinal bleeding,
Oral anticoagulants
Background
Warfarin is commonly used as a secondary prevention
of stroke in patients treated for Atrial Fibrillation (AF)
[1]. However, even if warfarin is used by majority of
patients, it also has limitations. Recently, several new
Direct Oral Anti-Coagulants (DOACs) have been ap-
proved for use by the Food and Drug Administrations
[2]. Even if these DOACs have previously been com-
pared to warfarin [3], they have seldom been compared
with each other in systematic reviews. The indirect
comparison of coronary risks associated with apixaban,
rivaroxaban and dabigatran showed significant differ-
ences in safety outcomes with regards to acute coronary
adverse events [4]. Moreover, a network meta-analysis
showed apixaban and 110 mg dabigatran twice a day to
be more effective in patients with non-valvular AF
whereas dabigatran 150 mg bid might be preferable
compared to rivaroxaban, for patients with a high risk
of embolism [5]. However, direct head-to-head com-
parison of rivaroxaban and dabigatran has seldom been
carried out. Therefore, this analysis aimed to compare
the bleeding events associated with rivaroxaban and
dabigatran in patients treated for AF.
Methods
Data sources and search strategy
English publications comparing rivaroxaban with
dabigatran were searched from EMBASE, Medline
(National Library of Medicine) and the Cochrane
Central Registry of Controlled Trials using the terms
‘rivaroxaban, dabigatran and atrial fibrillation’. To en-
hance this search, the words ‘new oral anticoagulants’
and the abbreviation ‘AF’ were also used. Moreover,
reference lists of potential articles were also searched
for relevant studies.
Inclusion and exclusion criteria
Studies were included if:
(a)They compared rivaroxaban with dabigatran.
(b)They consisted only of patients with AF.
(c)They reported bleeding events among their clinical
endpoints.
Studies were excluded if:
(a)They did not compare rivaroxaban with dabigatran,
but instead, compared them with other DOACs.
(b)They did not involve patients with AF.








The secondary outcomes analyzed were:




Refer to Table 1 for more details.
Data extraction and review
The studies were independently assessed by five au-
thors (PKB, MZSS, ART, MP, AB). The total number
of patients treated by rivaroxaban and dabigatran re-
spectively, the year of patients’ enrollment, the type
of study reported, the baseline features of the pa-
tients, the number of events reported, and the out-
comes analyzed were systematically extracted. The
bias risk was not assessed because this analysis only
involved data obtained from observational studies [6].
During this data extraction process, any disagreement
which occurred were discussed among the authors.
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However, if reaching a consensus was still difficult, a
final decision was made by the sixth author (WQH).
Statistical analysis
PRISMA (Preferred Reporting Items for Systematic Re-
views and Meta-Analyses) [7] guideline was followed.
Heterogeneity across the subgroups was assessed using
the Cochrane Q-statistic test (P ≤ 0 · 05 was considered
statistically significant) and the I2-statistic test. A fixed
effects model (I2 < 50%) or a random effects model
(I2 > 50%) was used depending on the value of I2.
Funnel plots were used to visually estimate publication
bias.
We calculated Odds Ratios (OR) with 95% Confidence
Intervals (CIs). The pooled analyses were carried out
with RevMan 5.3 software. Ethical approval was not re-
quired for this type of research.
All the authors had full access to the data and ap-
proved the manuscript as written.
Results
Search result
A total number of 1765 articles were obtained during
this search process. One thousand seven hundred
and thirty-two articles were eliminated since they
were not related to the topic of this search. Another
16 articles were eliminated since they were dupli-
cates. Seventeen full-text articles were assessed for
eligibility. However, further 12 articles were elimi-
nated since: five articles were meta-analyses, whereas
the remaining seven articles compared rivaroxaban or
dabigatran with other anticoagulants (apixaban, war-
farin). Finally, five articles were selected and included
in this meta-analysis (Fig. 1).
General features of the studies included
A total number of 4895 patients (1581 patients treated
by rivaroxaban and 3314 patients treated by dabigatran)
were included in this meta-analysis.
Table 2 summarizes the general features of the studies
included.
Baseline features of the studies included
The baseline features of the patients involved have been
summarized in Table 3.
The mean age of the patients ranged from 59.8 to
77.8 years. Dyslipidemia and current smoking were re-
ported in only one study. Study Larock2014 had the ma-
jority of patients with diabetes mellitus. According to
Table 3, there was no significant difference in baseline
features among patients treated with rivaroxaban and
dabigatran.
Bleeding events associated with rivaroxaban and
dabigatran
Results of this analysis have been summarized in
Table 4.
This analysis showed that rivaroxaban was not associ-
ated with a significantly higher bleeding events com-
pared to dabigatran (OR: 1.28, 95% CI: 0.95–1.72; P =
0.11, I2 = 0%). GI bleeding was similarly manifested be-
tween these two NOACs (OR: 0.98, 95% CI: 0.43–2.25;
P = 0.97, I2 = 0%). However, even if intracranial bleeding
was higher with rivaroxaban (OR: 2.18, 95% CI: 0.51–
9.25; P = 0.29, I2 = 0%), the result was not statistically sig-
nificant (Fig. 2).
Other clinical outcomes reported between rivaroxaban
and dabigatran
Apart from the bleeding events, other adverse out-
comes were also analyzed. Stroke/SE/TIA and venous
thromboembolism were not significantly different be-
tween these two groups (OR: 0.81, 95% CI: 0.53–1.23;
P = 0.32, I2 = 0%) and (OR: 2.06, 95% CI: 0.73–5.82; P
= 0.17, I2 = 0%) respectively. However, even if mortal-
ity favored dabigatran (OR: 1.42, 95% CI: 0.99–2.06;
P = 0.06, I2 = 38%), the result only approached statis-
tical significance (Fig. 3).
For the above analyses, sensitivity analyses yielded
consistent results. Based on a visual inspection of the
funnel plots obtained, there has been only little evidence
of publication bias for the included studies that assessed
bleeding outcomes and the other clinical outcomes re-
spectively (Figs. 4 and 5).
Table 1 Reported outcomes
Studies Reported outcomes Follow up period Types of patients
Gorst 2016 [8] Stroke/SE/TIA, any bleeding, death, intracranial bleeding, GI bleeding,
venous thromboembolism
1 year -
Larock 2014 [9] Stroke/TIA, venous thromboembolism, any bleeding, death - NVAF
Maura 2015 [10] Bleeding events, ischemic stroke/SE 3 months NVAF
Providencia 2014 [11] Death, thromboembolism, stroke, TIA, SE, major bleeding, minor bleeding 30 days -
Sherid 2014 [12] Major bleeding other than GI bleeding, intracranial hemorrhage, stroke/
TIA, venous thromboembolism, death, GI bleeding
40 days -
Abbreviations: SE systemic embolism, TIA transient ischemic attack, GI gastrointestinal, NVAF non-valvular atrial fibrillation
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Discussion
This analysis which aimed to compare (head to head)
the bleeding outcomes associated with rivaroxaban versus
dabigatran in patients treated for AF showed no signifi-
cant difference in bleeding events, including intracranial
and GI bleeding. Also, no significant difference was ob-
served in stroke/SE/TIA and venous thromboembolism.
However, mortality which was shown to favor dabigatran
only approached significance.
Five observational studies were included in this
current meta-analysis. The prospective cohort including
patients with non-valvular AF recruited between Febru-
ary 2012 to August 2014 (with new users of 15 mg or
20 mg rivaroxaban respectively who were older and as-
sociated with more co-morbidities compared to new
users with 110 or 150 mg dabigatran) showed rivaroxa-
ban to be associated with a lower or similar proportion
of stroke, but with an increased level of mortality and
bleeding compared to dabigatran [8]. Another prospect-
ive study used in this current analysis and including 69
patients showed adverse events with the use of rivaroxa-
ban and dabigatran respectively due to their inappropriate
use and suggested collaboration with clinical pharmacists
for better use of these drugs [9]. A French Nationwide
Propensity-Matched Cohort Study which has been used in
our current analysis showed similar bleeding and ischemic
Fig. 1 Flow diagram representing the study selection
Table 2 General features of the studies included
Studies Type of study Patients’ enrollment period No of patients in Rivaroxaban group (n) No of patients in Dabigatran group (n)
Gorst 2016 [8] Observational 2012–2014 360 1190
Larock 2014 [9] Observational - 35 34
Maura 2015 [10] Observational 2012 851 1687
Providencia 2014 [11] Observational 2012–2013 188 176
Sherid 2014 [12] Observational 2010–2013 147 227
Total no of patients (n) 1581 3314
Study Gorst 2016 included a very large number of patients. However, the other studies consisted of less patients. Therefore, in order for the result of this analysis
not to be influenced by the result of study Gorst 2016, only patients with diabetes mellitus were selected from that particular study
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risks between rivaroxaban versus warfarin, and dabigatran
and warfarin in the propensity-matched cohort [10]. In
addition, another study including 556 consecutive patients
showed both drug rivaroxaban and dabigatran to be effect-
ive and safe compared to warfarin [11]. Another head-to-
head comparison on the other hand showed dabigatran
and rivaroxaban to have a higher bleeding risk in the first
40 days, but dabigatran was not associated with an in-
creased risk of GI bleeding [12].
Previously, the indirect comparison involving 27 ran-
domized trials showed significant differences in the com-
parative safety of apixaban, rivaroxaban and dabigatran
[4]. However, these DOACs were individually compared
with warfarin whereby apixaban, rivaroxaban and dabi-
gatran showed different results from this current analysis
which compared rivaroxaban with dabigatran. Moreover,
the network meta-analysis involving data from the
RE-LY, ARISTOTLE and ROCKET AF trials, showed
apixaban to be safer compared to rivaroxaban or dabiga-
tran (150 mg) except that intracranial hemorrhage and all-
cause mortality were similarly manifested [5].
A study based in Australia showed both oral anticoag-
ulants to be associated with considerable amount of
hemorrhage within the first 30 days [13]. Two hundred
and forty hemorrhagic adverse events were observed
with rivaroxaban whereas 504 events were observed
among patients treated with dabigatran. But despite the
fact that a higher rate of bleeding events was observed
in both of the groups, rivaroxaban and dabigatran were
barely compared.
Another study which included 444 patients with par-
oxysmal, persistent and longstanding-persistent AF
showed comparable bleeding events between rivaroxa-
ban and dabigatran [14]. Even in the study published by
Fontaine et al, a comparable major bleeding events was
observed between these two DOACs [15]. Similar to this
current analysis, no significant difference in major com-
plications was observed between these two DOACs.
Also, a population based observational study showed a
similar rate of GI bleeding associated with DOACs and
warfarin [16] but the authors emphasized on the fact
that cautions should be taken when prescribing DOACs
to older patients.
In a recently published meta-analysis showing the im-
pact of DOACs on GI bleeding in patients with AF, the
authors concluded that rivaroxaban, edoxaban and higher
dosages of dabigatran should be avoided in patients who
are at higher risk of suffering from GI bleeding [17]. But
the fact that their study only aimed to investigate GI
bleeding associated with DOACs compared to warfarin
should not be ignored and their conclusion was inter-
preted in comparison to warfarin whereas this current
study compared rivaroxaban with dabigatran, instead of
rivaroxaban with warfarin and dabigatran with warfarin
respectively.
Coronary risk was also compared among the DOACs
(dabigatran, apixaban and rivaroxaban), but even if a
signal of increased coronary risk was observed with
dabigatran, no direct comparison was made [18] imply-
ing that head to head comparison was a major limita-
tion in that study.
Another meta-analysis published by Caldeira et al
showed that DOACs might be as safe as warfarin in pa-
tients who were to be treated for non-valvular AF [19].
In addition, the study published by Yao et al, using pa-
tients from a large United States database, showed that
in patients with non-valvular AF, dabigatran was associ-
ated with a similar rate of stroke, but with a lower rate
of major bleeding when compared to warfarin [20]. Also,
when warfarin and rivaroxaban were compared, the lat-
ter was associated with similar rate of stroke and major
bleeding. The network meta-analysis comparing the ef-
fectiveness of interventions for stroke prevention in pa-
tients with AF also showed all oral anticoagulants to
reduce stroke/systemic embolism and mortality [21].
Randomized trials have been conducted so far only to
compare each of the DOACs with warfarin. However, no
randomized trial has been conducted to show a head-to-
head comparison between two different DOACs. There
might be underlying market agreements aimed at
Table 3 Baseline features
Studies Mean age Males (%) Ht (%) Ds (%) Cs (%) DM (%)




































Abbreviations: R rivaroxaban, D dabigatran, Ht hypertension, Ds dyslipidemia, Cs current smoker, DM diabetes mellitus
Table 4 Results of this analysis

























Abbreviations: SE systemic embolism, TIA transient ischemic attack, OR odds
ratios, CI confidence interval
Bundhun et al. BMC Cardiovascular Disorders  (2017) 17:15 Page 5 of 9
avoiding conflicts of similar products, in view of the
common goal, which is to subtract market space to
Vitamin K antagonists.
DOACs might be cost-effective [22] but their benefits
should be further studied for future care. The Canada-
based study comparing rivaroxaban with dabigatran in
patients treated for AF found dabigatran to be econom-
ically dominant for the prevention of stroke and SE [23].
The study by Miguel et al also showed dabigatran to im-
prove clinical events with a lower cost, and it was pre-
ferred to rivaroxaban in Portuguese patients who
suffered from AF [24].
However, these hypotheses will have to be further
proved in newer randomized trials beginning with the
PREFER-AF trial which should be the first randomized
trial evaluating vascular protective effects of these
Fig. 2 Bleeding events associated with rivaroxaban and dabigatran
Fig. 3 Adverse clinical outcomes associated with rivaroxaban and dabigatran
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DOACs [25]. The overall use of these DOACs will
also depend on several factors such as patient satis-
faction, cost, and risk profile of patients. Currently, it
should not be ignored that the CHADS2-VASC score
is used to assess patients for the risk of stroke
whereas the HAS-BLED score is used to calculate the
risk of bleeding in patients who are treated by oral
anticoagulants [26, 27]. Renal function should also be
taken into account before considering DOACs in pa-
tients with non-valvular AF [28].
Novelty
The idea of this research is new in clinical medicine.
Several DOACs have been approved for use in this new
era. However, even if they have previously been com-
pared with warfarin, they have seldom been directly
compared with each other in systematic reviews and
meta-analyses. By comparing rivaroxaban with dabiga-
tran, this direct head to head analysis represents a new
feature contributing to the literature of clinical medicine.
Moreover, despite of including data obtained from ob-
servational studies, a very low level of heterogeneity was
observed among all the subgroups analyzed which might
be another new feature of this study.
Limitations
This study also has limitations. First of all, due to the re-
stricted number of patients, this analysis might not
Fig. 4 Funnel plots showing publication bias
Fig. 5 Funnel plots showing publication bias
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provide robust results. In addition, only data from ob-
servational studies were included. Since data obtained
from observational studies are not expected to be as
good as data obtained from randomized trials, an-
other limitation might be considered. Heterogeneous
data which were included might also affect the re-
sults. Moreover, when analyzing stroke/SE/TIA, two
studies which did not include TIA and SE respect-
ively, were also included in this subgroup and ana-
lyzed due to a lack of data. This might also affect the
result of this analysis. The follow-up periods reported
in each study involved were also ignored, further con-
tributing to the limitations in this study.
Conclusion
Head to head comparison showed that rivaroxaban
was not associated with significantly higher bleeding
events compared to dabigatran. Intracranial bleeding,
GI bleeding, stroke/SE/TIA, venous thromboembolism
and mortality were also not significantly different be-
tween these two DOACs. However, due to the limited
number of patients analyzed, and which were mainly
obtained from observational studies, this hypothesis
might only be confirmed in future randomized trials.
Furthermore, the CHADS2-VASC and HAS-BLED
score which might play an important role in predict-
ing bleeding risks should also not be ignored.
Abbreviations
AF: Atrial fibrillation; CI: Confidence intervals; DOACs: New direct oral
anticoagulants; GI bleeding: Gastrointestinal bleeding; OR: Odds ratios;
SE: Systemic embolism
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